SCHEMBL17367885

SCHEMBL17367885

CS/C(=C\C(=O)c1ccccc1)Nc1cccc2c(N/C(=C/C(=O)c3ccccc3)SC)cccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.54
MEN1 O00255 5/20 0.54
RAB9A P51151 8/20 0.45
NPC1 O15118 7/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
MAPT P10636 7/20 0.44
GAA P10253 4/20 0.44
THRB P10828 1/20 0.44
NFE2L2 Q16236 1/20 0.42
MAPK1 P28482 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
PARP1 P09874 2/20 0.42
TP53 P04637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
KDM4E B2RXH2 4/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15983757 0.93 KMT2A (0.48) KMT2AMEN1RAB9ANPC1CYP1A2
SCHEMBL31144971 0.83 MEN1 (0.62) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL31144977 0.83 MEN1 (0.62) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL7986877 0.78 MEN1 (0.65) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL31145003 0.78 MEN1 (0.65) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL3074598 0.73 RAB9A (0.60) KMT2AMEN1RAB9ANPC1CYP1A2
SCHEMBL3074602 0.73 RAB9A (0.60) KMT2AMEN1RAB9ANPC1CYP1A2
SCHEMBL5931216 0.72 MAPT (0.59) KMT2AMEN1RAB9ACYP1A2CYP3A4
SCHEMBL5931211 0.72 MAPT (0.59) KMT2AMEN1RAB9ACYP1A2CYP3A4
SCHEMBL5931217 0.72 MAPT (0.59) KMT2AMEN1RAB9ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9748497-B2 Electronic device including a diazachrysene derivative E I DU PONT DE NEMOURS AND COMPANY (US) 2017-08-29 US disclosed
US-9748497-B2 Electronic device including a diazachrysene derivative E I DU PONT DE NEMOURS AND COMPANY (US) 2017-08-29 US disclosed
US-20150380664-A1 ELECTRONIC DEVICE INCLUDING A DIAZACHRYSENE DERIVATIVE LG CHEM, LTD. (KR) 2015-12-31 US disclosed
US-20150380664-A1 ELECTRONIC DEVICE INCLUDING A DIAZACHRYSENE DERIVATIVE LG CHEM, LTD. (KR) 2015-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150380664-A1 ELECTRONIC DEVICE INCLUDING A DIAZACHRYSENE DERIVATIVE DDT, CCNE2, DERL1 KMT2A 1165/4885MEN1 786/4885RAB9A 1016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.